Ads
related to: polycythemia vera and surgery risks and side effects
Search results
Results from the WOW.Com Content Network
In oncology, polycythemia vera (PV) is an uncommon myeloproliferative neoplasm in which the bone marrow makes too many red blood cells. [1] The majority of cases [ 2 ] are caused by mutations in the JAK2 gene, most commonly resulting in a single amino acid change in its protein product from valine to phenylalanine at position 617.
Polycythemia vera (PCV) (a.k.a. polycythemia rubra vera (PRV)) occurs when excess red blood cells are produced as a result of an abnormality of the bone marrow. [3] Often, excess white blood cells and platelets are also produced. A hallmark of polycythemia vera is an elevated hematocrit, with Hct > 55% seen in 83% of cases. [20]
Therapeutic phlebotomy refers to the drawing of a unit of blood in specific cases like hemochromatosis, polycythemia vera, porphyria cutanea tarda, etc., to reduce the number of red blood cells. [ 6 ] [ 7 ] The traditional medical practice of bloodletting is today considered to be a pseudoscience .
Myeloproliferative neoplasms including polycythemia vera and essential thrombocythemia [40] Nonsyndromic hearing loss and deafness, DFNB1 (connexin 26) [41] Parkinson's disease (G2019S/LRRK2 mutation; [42] The LRRK2 mutation on the main haplotype, shared by Ashkenazi Jews, North Africans, and Europeans, initially arose in the Near East at least ...
LMWH is recommended for at least 7–10 days following cancer surgery, and for one month following surgery for people who have a high risk of VTEs. [ 40 ] [ 39 ] Specifically for patients with various types of lymphoma, there is a risk assessment model, ThroLy , to help providers determine how likely a thromboembolic event is to occur.
Risk factors include exposure to an agent known to cause DNA damage, such as radiation, benzene, and certain chemotherapies; other risk factors have been inconsistently reported. Proving a connection between a suspected exposure and the development of MDS can be difficult, but the presence of genetic abnormalities may provide some supportive ...
Particular blood disorders, especially polycythemia vera and paroxysmal nocturnal hemoglobinuria; Use of estrogen-containing forms of hormonal contraception; Meningitis and infections of the ear, nose and throat area such as mastoiditis and sinusitis; Direct injury to the venous sinuses; Medical procedures in the head and neck area
Hydroxycarbamide, also known as hydroxyurea, is an antimetabolite medication used in sickle-cell disease, essential thrombocythemia, chronic myelogenous leukemia, polycythemia vera, and cervical cancer. [4] [5] In sickle-cell disease it increases fetal hemoglobin and decreases the number of attacks. [4] It is taken by mouth. [4]
Ads
related to: polycythemia vera and surgery risks and side effects